eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma

BACKGROUND: Immune checkpoint blockade (ICB) targeting programmed death ligand-1 (PD-L1)/programmed cell death protein-1 (PD-1) pathway has become an attractive strategy for cancer treatment; however, unsatisfactory efficacy has limited its clinical benefits. Therefore, a more comprehensive understa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xisha, Wang, Kuansong, Jiang, Shilong, Sun, Hongyin, Che, Xuanling, Zhang, Minghui, He, Jiaying, Wen, Ying, Liao, Mengting, Li, Xiangling, Zhou, Xiaoming, Song, Jianxun, Ren, Xingcong, Yi, Wenjun, Yang, Jinming, Chen, Xiang, Yin, Mingzhu, Cheng, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961175/
https://www.ncbi.nlm.nih.gov/pubmed/35347072
http://dx.doi.org/10.1136/jitc-2021-004026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961175/
https://www.ncbi.nlm.nih.gov/pubmed/35347072
http://dx.doi.org/10.1136/jitc-2021-004026

Ejemplares similares